Principles of safety pharmacology.

The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol (2009) 2.26

An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br J Pharmacol (2010) 2.23

Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis (2010) 2.08

How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol (2011) 1.19

Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk. Br J Pharmacol (2011) 1.12

Computational assessment of drug-induced effects on the electrocardiogram: from ion channel to body surface potentials. Br J Pharmacol (2013) 1.09

Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. Br J Pharmacol (2011) 1.08

Evaluation of an in silico cardiac safety assay: using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge. J Pharmacol Toxicol Methods (2013) 1.01

Value of non-clinical cardiac repolarization assays in supporting the discovery and development of safer medicines. Br J Pharmacol (2010) 0.95

Species differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirus. Mol Pharm (2010) 0.86

In question: the scientific value of preclinical safety pharmacology and toxicology studies with cell-based therapies. Mol Ther Methods Clin Dev (2014) 0.84

Cassia auriculata: Aspects of Safety Pharmacology and Drug Interaction. Evid Based Complement Alternat Med (2011) 0.84

Predicting the emetic liability of novel chemical entities: a comparative study. Br J Pharmacol (2012) 0.83

Induced pluripotent stem cells for regenerative cardiovascular therapies and biomedical discovery. Adv Drug Deliv Rev (2011) 0.81

The electromechanical window is no better than QT prolongation to assess risk of Torsade de Pointes in the complete atrioventricular block model in dogs. Br J Pharmacol (2014) 0.80

Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates. AAPS J (2015) 0.79

Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2. Br J Pharmacol (2012) 0.78

Biomarkers and endogenous determinants of dofetilide-induced torsades de pointes in α(1) -adrenoceptor-stimulated, anaesthetized rabbits. Br J Pharmacol (2010) 0.78

Evaluation of drug-induced QT interval prolongation in animal and human studies: a literature review of concordance. Br J Pharmacol (2015) 0.77

Dopamine D3 Receptor Antagonist (GSK598809) Potentiates the Hypertensive Effects of Cocaine in Conscious, Freely-Moving Dogs. J Pharmacol Exp Ther (2015) 0.77

Mediators and receptors in the resolution of inflammation: drug targeting opportunities. Br J Pharmacol (2009) 0.75

Continuity and change. Br J Pharmacol (2009) 0.75

Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies. Braz J Med Biol Res (2016) 0.75

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 12.98

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med (2006) 9.07

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (2007) 6.76

International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed Regist (2005) 4.86

Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia (1968) 4.59

Torsades de pointes occurring in association with terfenadine use. JAMA (1990) 3.93

HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation (1996) 2.46

Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. Am J Cardiol (1994) 2.14

The neurocircuitry of addiction: an overview. Br J Pharmacol (2008) 2.11

Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation (2004) 2.09

Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm (2005) 2.07

Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm (2006) 2.03

Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci (2005) 1.90

T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. Clin Sci (Lond) (2003) 1.86

Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend (2003) 1.71

Transient outward potassium current, 'Ito', phenotypes in the mammalian left ventricle: underlying molecular, cellular and biophysical mechanisms. J Physiol (2005) 1.63

Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J Clin Pharmacol (2006) 1.57

A comprehensive review and analysis of 25 years of data from an in vivo canine model of sudden cardiac death: implications for future anti-arrhythmic drug development. Pharmacol Ther (2006) 1.55

Chaos and the transition to ventricular fibrillation: a new approach to antiarrhythmic drug evaluation. Circulation (1999) 1.54

Origins, practices and future of safety pharmacology. J Pharmacol Toxicol Methods (2004) 1.49

Molecular determinants of HERG channel block. Mol Pharmacol (2006) 1.49

Antihistamines--is there anything safe to prescribe? Ann Allergy (1992) 1.44

Responses to ligation of a coronary artery in conscious rats and the actions of antiarrhythmics. Can J Physiol Pharmacol (1983) 1.36

Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer (2008) 1.34

Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend (2003) 1.30

Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead. Drug Saf (2005) 1.29

High throughput assay technologies for ion channel drug discovery. Assay Drug Dev Technol (2004) 1.28

A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes. Br J Pharmacol (2006) 1.21

The value of nonhuman primates in drug abuse research. Exp Clin Psychopharmacol (2007) 1.19

Characterisation, utilisation and clinical relevance of isolated perfused heart models of ischaemia-induced ventricular fibrillation. Cardiovasc Res (1998) 1.13

Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog. Agents Actions (1985) 1.09

Detection of proarrhythmia in the female rabbit heart: blinded validation. J Cardiovasc Electrophysiol (2003) 1.05

Study of histamine release induced by acute administration of antitumor agents in dogs. Cancer Chemother Pharmacol (1988) 1.01

The second wave in kinase cancer drugs. Nat Biotechnol (2006) 1.00

QT PRODACT: in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. J Pharmacol Sci (2005) 1.00

Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. J Pharmacol Toxicol Methods (2004) 1.00

Refinements in telemetry procedures. Seventh report of the BVAAWF/FRAME/RSPCA/UFAW Joint Working Group on Refinement, Part A. Lab Anim (2003) 0.96

Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies. J Pharmacol Toxicol Methods (2005) 0.96

Preclinical assessment of drug-induced proarrhythmias: role of the arterially perfused rabbit left ventricular wedge preparation. Pharmacol Ther (2008) 0.95

Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J Pharmacol Toxicol Methods (2008) 0.92

An optimised methodology for the neurobehavioural assessment in rodents. J Pharmacol Toxicol Methods (2007) 0.92

QT PRODACT: comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans. J Pharmacol Sci (2005) 0.90

Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen. Assay Drug Dev Technol (2005) 0.90

Which cardiac potassium channel subtype is the preferable target for suppression of ventricular arrhythmias? Pharmacol Ther (1996) 0.89

Arrhythmias associated with myocardial ischaemia and infarction. Mol Aspects Med (1985) 0.87

QT PRODACT: in vivo QT assay in anesthetized dog for detecting the potential for QT interval prolongation by human pharmaceuticals. J Pharmacol Sci (2005) 0.87

QT PRODACT: in vivo QT assay with a conscious monkey for assessment of the potential for drug-induced QT interval prolongation. J Pharmacol Sci (2005) 0.87

Arrhythmogenic mechanisms of non-sedating antihistamines. Clin Exp Allergy (1999) 0.86

QT PRODACT: inter-facility variability in electrocardiographic and hemodynamic parameters in conscious dogs and monkeys. J Pharmacol Sci (2005) 0.85

Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? Am J Cardiol (1998) 0.85

Cardiovascular monkey telemetry: sensitivity to detect QT interval prolongation. J Pharmacol Toxicol Methods (2006) 0.85

Identification of novel Kv1.3 blockers using a fluorescent cell-based ion channel assay. J Biomol Screen (2005) 0.85

Sensitivity and specificity of isolated perfused guinea pig heart to test for drug-induced lengthening of QTc. J Pharmacol Toxicol Methods (2003) 0.85

A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. J Pharmacol Toxicol Methods (2007) 0.84

Cardiovascular parameters in anaesthetized guinea pigs: a safety pharmacology screening model. J Pharmacol Toxicol Methods (2005) 0.83

Limited antifibrillatory effectiveness of clinically relevant concentrations of class I antiarrhythmics in isolated perfused rat hearts. J Cardiovasc Pharmacol (2002) 0.82

Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel. J Pharmacol Toxicol Methods (2005) 0.82

A canine model used to simultaneously assess potential neurobehavioural and cardiovascular effects of candidate drugs. J Pharmacol Toxicol Methods (2007) 0.81

Integration of safety pharmacology endpoints into toxicology studies. Fundam Clin Pharmacol (2002) 0.81

Commercial development considerations for biotechnology-derived therapeutics. Cardiovasc Toxicol (2003) 0.81

Animal models of ventricular arrhythmias. Pharmacol Ther (2006) 0.80

If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed? Pharmacol Ther (2008) 0.80

Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. J Pharmacol Toxicol Methods (2007) 0.80

A cardiovascular monitoring system used in conscious cynomolgus monkeys for regulatory safety pharmacology. Part 2: Pharmacological validation. J Pharmacol Toxicol Methods (2007) 0.80

Benchmarking safety pharmacology regulatory packages and best practice. J Pharmacol Toxicol Methods (2008) 0.79

QT PRODACT: sensitivity and specificity of the canine telemetry assay for detecting drug-induced QT interval prolongation. J Pharmacol Sci (2005) 0.79

Safety pharmacology matures into a unique pharmacological discipline. J Pharmacol Toxicol Methods (2004) 0.79

An in vitro method for the evaluation of antiarrhythmic and antiischemic agents by using programmed electrical stimulation of rabbit heart. J Pharmacol Toxicol Methods (1994) 0.79

Evaluation of the guinea pig monophasic action potential (MAP) assay in predicting drug-induced delay of ventricular repolarisation using 12 clinically documented drugs. J Pharmacol Toxicol Methods (2007) 0.78

Torsades de pointes with terfenadine ingestion. Am J Emerg Med (1997) 0.78

Arrhythmia models in the rat. J Pharmacol Toxicol Methods (1993) 0.78

The evaluation of the abuse liability of drugs. Drug Saf (1990) 0.78

Spectrum of effects detected in the rat functional observational battery following oral administration of non-CNS targeted compounds. J Pharmacol Toxicol Methods (2005) 0.76

Validation of respiratory safety pharmacology models: conscious and anesthetized beagle dogs. J Pharmacol Toxicol Methods (2007) 0.76

The use of the dog electroencephalogram (EEG) in safety pharmacology to evaluate proconvulsant risk. J Pharmacol Toxicol Methods (2007) 0.76

Respiratory and cardiovascular changes associated with toxic doses of a peptide antagonist of vasopressin in the rat. Fundam Appl Toxicol (1992) 0.76

Mechanism of hypotension following rapid infusion of protamine sulfate in anesthetized dogs. J Cardiothorac Vasc Anesth (1992) 0.76

Of oocytes and runny noses. Circulation (1996) 0.76

The influence of extracellular acidosis on the effect of IKr blockers. J Cardiovasc Pharmacol Ther (2005) 0.76

Introduction to nonclinical safety pharmacology and the safety pharmacology society. J Pharmacol Toxicol Methods (2004) 0.76

The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc Res (1988) 3.98

Validation of three myocardial jeopardy scores in a population-based cardiac catheterization cohort. Am Heart J (2001) 1.55

Models for the study of arrhythmias in myocardial ischaemia and infarction: the use of the rat. J Mol Cell Cardiol (1987) 1.34

The action of dilute aqueous NN-dimethylhydrazine on bacterial cell walls. Biochem J (1969) 1.24

Antiarrhythmic actions of verapamil against ischaemic arrhythmias in the rat. Br J Pharmacol (1984) 1.21

Studies on the structure of intracellular bacteriophage T4 DNA. J Mol Biol (1976) 1.11

IK1 blockade is a potentially useful antiarrhythmic mechanism. Cardiovasc Res (1994) 1.10

A shared DNA-damage-response pathway for induction of stem-cell death by UVB and by gamma irradiation. DNA Repair (Amst) (2010) 1.07

An improved perfusion apparatus for small animal hearts. J Pharmacol Methods (1986) 1.07

The effects of ablations in the central nervous system on arrhythmias induced by coronary occlusion in the rat. Br J Pharmacol (1985) 1.04

Influence of tedisamil on the initiation and maintenance of ventricular fibrillation: chemical defibrillation by Ito blockade? J Cardiovasc Pharmacol (1991) 1.04

Specific IK1 blockade: a new antiarrhythmic mechanism? Effect of RP58866 on ventricular arrhythmias in rat, rabbit, and primate. Circulation (1993) 1.03

Effects of NO modulation on cardiac arrhythmias in the rat isolated heart. Circ Res (1995) 1.01

Ischemia-induced and reperfusion-induced arrhythmias: importance of heart rate. Am J Physiol (1989) 1.00

Lanthanum as a surrogate for calcium in transmitter release at mouse motor nerve terminals. J Physiol (1986) 0.98

Brief, intermediate and prolonged ischemia in the isolated crystalloid perfused rat heart: relationship between susceptibility to arrhythmias and degree of ultrastructural injury. J Mol Cell Cardiol (1995) 0.97

A new method of arthroscopic reconstruction of the dislocated acromio-clavicular joint. Ann R Coll Surg Engl (2004) 0.96

The mechanism of action of the optical enantiomers of verapamil against ischaemia-induced arrhythmias in the conscious rat. Br J Pharmacol (1986) 0.96

Nitric oxide attenuates neutrophil-mediated myocardial contractile dysfunction after ischemia and reperfusion. Circ Res (1996) 0.96

High-fidelity readout of trapped-ion qubits. Phys Rev Lett (2008) 0.93

Anatomical restraints to dislocation of the second metatarsophalangeal joint and assessment of a repair technique. J Bone Joint Surg Am (1994) 0.92

Pharmacological analysis in rat of the role of the ATP-sensitive potassium channel as a potential target for antifibrillatory intervention in acute myocardial ischaemia. J Cardiovasc Pharmacol (1995) 0.90

Actions of the verapamil analogues, anipamil and ronipamil, against ischaemia-induced arrhythmias in conscious rats. Br J Pharmacol (1986) 0.90

Which cardiac potassium channel subtype is the preferable target for suppression of ventricular arrhythmias? Pharmacol Ther (1996) 0.89

Quantitative anatomical basis for a model of micromechanical frequency tuning in the Tokay gecko, Gekko gecko. Hear Res (1995) 0.88

Arrhythmias associated with myocardial ischaemia and infarction. Mol Aspects Med (1985) 0.87

Inadequate ischaemia-selectivity limits the antiarrhythmic efficacy of mibefradil during regional ischaemia and reperfusion in the rat isolated perfused heart. Br J Pharmacol (1999) 0.87

A modified model of global ischaemia: application to the study of syncytial mechanisms of arrhythmogenesis. Cardiovasc Res (1992) 0.87

Effect of endogenous nitric oxide on cardiac systolic and diastolic function during ischemia and reperfusion in the rat isolated perfused heart. J Mol Cell Cardiol (1996) 0.86

Selective IK blockade as an antiarrhythmic mechanism: effects of UK66,914 on ischaemia and reperfusion arrhythmias in rat and rabbit hearts. Br J Pharmacol (1993) 0.86

Combined administration of an IK(ATP) activator and Ito blocker increases coronary flow independently of effects on heart rate, QT interval, and ischaemia-induced ventricular fibrillation in rats. J Cardiovasc Pharmacol (1993) 0.86

The effect of Escherichia coli endotoxins on the concentrations of corticosterone and growth hormone in the plasma of the domestic fowl. Res Vet Sci (1980) 0.85

An endogenous protectant effect of cardiac cyclic GMP against reperfusion-induced ventricular fibrillation in the rat heart. Br J Pharmacol (1995) 0.85

Tacrine inhibits ventricular fibrillation induced by ischaemia and reperfusion and widens QT interval in rat. Cardiovasc Res (1993) 0.85

Endogenous protection against reperfusion-induced ventricular fibrillation: role of neuronal versus non-neuronal sources of nitric oxide and species dependence in the rat versus rabbit isolated heart. J Mol Cell Cardiol (1996) 0.85

Effects of (-), (+/- ), and (+) verapamil on coronary occlusion-induced mortality and infarct size. J Cardiovasc Pharmacol (1987) 0.84

Mechanism of 5-hydroxytryptamine-induced coronary vasodilation assessed by direct detection of nitric oxide production in guinea-pig isolated heart. Br J Pharmacol (1996) 0.84

Involvement of 5-HT(1B/1D) and 5-HT2A receptors in 5-HT-induced contraction of endothelium-denuded rabbit epicardial coronary arteries. Br J Pharmacol (1997) 0.84

The effect of Escherichia coli endotoxin on the plasma iron concentration in the domestic fowl. Res Vet Sci (1973) 0.84

The actions of felodipine on arrhythmias and other responses to myocardial ischaemia in conscious rats. Eur J Pharmacol (1985) 0.84

Anion manipulation: a new antiarrhythmic approach. Action of substitution of chloride with nitrate on ischemia- and reperfusion-induced ventricular fibrillation and contractile function. Circ Res (1992) 0.83

Reperfusion and readmission of oxygen. Pathophysiological relevance of oxygen-derived free radicals to arrhythmogenesis. Circ Res (1990) 0.81

Acute lateral dislocation of the patella: correlation of ultrasound scanning with operative findings. Injury (2003) 0.81

Protection by cimetidine, but not ranitidine, implies that H2 receptors do not mediate arrhythmogenesis in a rat model of regional ischaemia and reperfusion in vitro. Cardiovasc Res (1995) 0.80

Computerized templating in uncemented total hip arthroplasty to assess component fit and fill. J Arthroplasty (1992) 0.80

Further investigations into the mechanism of antifibrillatory action of the specific IK1 blocker, RP58866, assessed using the rat dual coronary perfusion model. J Mol Cell Cardiol (1995) 0.80

Osteomyelitis of the symphysis pubis after inguinal hernia repair. Ann R Coll Surg Engl (1996) 0.80

Nasal response to capsaicin in patients with allergic rhinitis and in healthy volunteers: effect of colchicine. Am J Respir Crit Care Med (1995) 0.79

Innovation in safety pharmacology testing. J Pharmacol Toxicol Methods (2011) 0.79

Protection against ventricular fibrillation by the PAF antagonist, BN-50739, involves an ischaemia-selective mechanism. J Cardiovasc Pharmacol (1999) 0.79

Mechanism of actions of sumatriptan on coronary flow before and after endothelial dysfunction in guinea-pig isolated heart. Br J Pharmacol (1997) 0.79

Correlation of waiting time with adverse events in patients admitted for nonelective permanent pacemaker implantation. Can J Cardiol (1998) 0.78

Independent dual perfusion of left and right coronary arteries in isolated rat hearts. Am J Physiol (1991) 0.78

Experimental recovery of a qubit from partial collapse. Phys Rev Lett (2013) 0.78

Musculoskeletal injuries in the Afghan war. Injury (1992) 0.78

Nupafant, a PAF-antagonist prototype for suppression of ventricular fibrillation without liability for QT prolongation? Br J Pharmacol (2006) 0.78

Modulation of ventricular arrhythmias by catecholamines during evolving infarction in the isolated perfused rat heart. Proc West Pharmacol Soc (2001) 0.77

Augmentation of patellar tendon repair with poly-p-dioxannone cord. Injury (2002) 0.77

Are reperfusion-induced arrhythmias caused by disinhibition of an arrhythmogenic component of ischemia? J Mol Cell Cardiol (1990) 0.77

Response of caeruloplasmin to Escherichia coli endotoxins and adrenal hormones in the domestic fowl. Res Vet Sci (1980) 0.76

Effects of atrial natriuretic peptide on ischaemia-induced arrhythmias in the rat heart: arrhythmogen or endogenous antiarrhythmic agent? J Cardiovasc Pharmacol (1989) 0.76

Strongyle resistance to fenbendazole in horses. Can Vet J (2000) 0.75

Nitric oxide fails to confer endogenous antiarrhythmic cardioprotection in the primate heart in vitro. Br J Pharmacol (2007) 0.75

Nitrates in drinking water: relationship to cardiac death. Eur Heart J (1990) 0.75

Bacterial endotoxins and the pathogenesis of fatty liver--haemorrhagic syndrome in the laying hen. Res Vet Sci (1981) 0.75

Escherichia coli endotoxin as a stressor in the domestic fowl. Res Vet Sci (1977) 0.75

Bacterial endotoxins and liver haemorrhage in the oestrogenised chicken. Res Vet Sci (1980) 0.75

Effect of infectious bronchitis on the structure and composition of egg albumen. J Sci Food Agric (1972) 0.75

Factors related to susceptibility and recruitment by cults. Psychol Rep (1993) 0.75

The effects of Escherichia coli endotoxin and ACTH on the plasma zinc concentration in the domestic fowl. Res Vet Sci (1973) 0.75

The effect of heat killed Mycoplasma gallisepticum and M. meleagridis on plasma caeruloplasmin activity in the fowl. Res Vet Sci (1973) 0.75

Evaluation of acetabular stability in uncemented prostheses. J Arthroplasty (1991) 0.75

Is it worthwhile to offer repeat hydrodilatation for frozen shoulder after 6 weeks? Int J Clin Pract (2009) 0.75

Non-clinical models: validation, study design and statistical consideration in safety pharmacology. J Pharmacol Toxicol Methods (2010) 0.75

Patlak plot analysis CT-GFR for the determination of renal function: comparison of normal dogs with autologous kidney transplant dogs. Contrast Media Mol Imaging (2010) 0.75

Methodological innovations expand the safety pharmacology horizon. J Pharmacol Toxicol Methods (2012) 0.75

Effect of Escherichia coli O78 endotoxin on plasma lipids in the domestic fowl. Res Vet Sci (1980) 0.75

The effects of Escherichia coli endotoxin on the concentrations of mineral elements in the plasma of the domestic fowl. Res Vet Sci (1975) 0.75

Effect of Escherichia coli endotoxins on plasma para-phenylenediamine oxidase (caeruloplasmin) activity in the domestic fowl. J Comp Pathol (1972) 0.75

Coronary aneurysms and ankylosing spondylitis: what stenting option is truly optimal? Int J Cardiol (2006) 0.75

The effect of Escherichia coli endotoxin on plasma histaminase activity in the domestic fowl and the involvement of caeruloplasmin. Res Vet Sci (1977) 0.75

Nitric oxide: an endogenous cardioprotectant? EXS (1996) 0.75

The effect of Escherichia coli endotoxins and adrenocortical hormones on plasma enzyme activities in the domestic fowl. Res Vet Sci (1980) 0.75

The effect of Escherichia coli endotoxin on lysosomal enzymes in the domestic fowl. Res Vet Sci (1977) 0.75

Eponyms, priority, and attribution. Cardiovasc Res (1992) 0.75

Use of the Shirodkar suture in shoulder surgery. Ann R Coll Surg Engl (2003) 0.75

Identification of chicken major histocompatibility complex (B) haplotypes by an immunoblot technique. J Immunol Methods (1986) 0.75

The influence of Escherichia coli O78 endotoxin on carbohydrate metabolism in the domestic fowl. Res Vet Sci (1981) 0.75